Vet Pathol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millanta, F.
Right arrow Articles by Poli, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millanta, F.
Right arrow Articles by Poli, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Vet Pathol 39:120-126 (2002)
© 2002 American College of Veterinary Pathologists

MIB-1 Labeling Index in Feline Dysplastic and Neoplastic Mammary Lesions and Its Relationship with Postsurgical Prognosis

F. Millanta, G. Lazzeri, M. Mazzei, I. Vannozzi and A. Poli

Department of Animal Pathology, School of Veterinary Medicine, University of Pisa, 2 I-56124 Pisa, Italy (FM, GL, MM, AP); and Clinic Department, School of Veterinary Medicine, University of Pisa, 1 I-56124 Pisa, Italy (IV)


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Samples from feline normal, dysplastic, and neoplastic mammary tissues were used to investigate the usefulness of MIB-1 labeling index (MIB-1 I) as a prognostic indicator. Forty-eight queens bearing invasive carcinomas were included in a 2-year follow-up study. Mammary lesions were classified according to the World Health Organization system, and invasive carcinomas were further graded on the basis of the degree of tubule formation, the degree of nuclear and cellular pleomorphism, and mitotic count. Additional sections were immunostained using MIB-1 antibody, and MIB-1 I was expressed as a percentage of positive nuclei. In normal mammary gland tissues, the mean MIB-1 I was <1%. A low proliferation rate was found in all mammary adenosis and in situ carcinomas, and the highest rates were observed in feline mammary hypertrophy and invasive carcinomas. Twenty-one (43.7%) of the queens bearing invasive carcinomas were still alive at the end of the trial, and 27 (56.2%) had died. The MIB-1 I was not significantly correlated with clinical outcome, age, histologic type, or grading of the tumors, but a borderline correlation was observed with invasion of lymphatic vessels. Univariate analysis showed that high MIB-1 I was also not associated with decreased overall survival, whereas the grading system of the tumors had high predictive value (P = 0.0040) for postsurgery survival. The lack of correlation between MIB-1 I and postsurgery survival suggests that this marker alone is not sufficient to determine a correct prognosis in feline mammary carcinomas, even if it is a useful proliferation marker.

Key words: Cats; grading; immunohistochemistry; mammary dysplasias; mammary tumors; MIB-1; prognostic significance.

Mammary tumors are commonly obsreved in female cats.1 Between 80% and 96% of these tumors are malignant and very aggressive10,18, and can grow rapidly and metastatize to regional lymph nodes, spleen, liver, and lung.11,17 For these reasons, these tumors are an important cause of mortality, especially in middle-aged and elderly females. The interval between feline mammary carcinoma (FMC) detection and death varies from <6 to 12 months.18 Several factors, including age, diameter of the primary lesion, the presence of histologically tumor-positive lymph nodes, mitotic count, extent of necrosis, and complete surgical excision, are independently correlated with postsurgery survival time. A radical surgical treatment instead of a conservative one is significantly related to the disease-free interval.16,23 In the last decades, the interest of veterinary pathologists has been focused on the assessment of markers that may improve the prognosis of FMC, such as morphologic features2,23 and the proliferative activity of the tumor.3,20 In human oncology, the immunohistochemical detection of cell proliferation–associated antigens has been widely investigated. One of the most useful reagents in this field is the antibody to Ki-67 antigen, a nonhistone, highly protease-sensitive nuclear protein, whose expression is strictly associated with cell proliferation.8,22 Ki-67 antigen is expressed in all phases of continuously cycling cells, except G0 and G1.7 Thus, it is an excellent marker for determining the so-called growth fraction of a given cell population. Antibodies directed against this protein are widely used in evaluation of tumors, especially mammary tumors. The Ki-67 labeling index (percentage of positive nuclei) is often correlated with the clinical course of the disease.12,22 The MIB-1 monoclonal antibody (MIB-1) directed against this antigen produces a cross-reaction in frozen and paraffin-embedded feline tissue sections.13

The few studies on the determination of cell proliferation activity of canine and feline mammary tumors by the immunohistochemical detection of Ki-67 antigen have produced contradictory results.4,15,19 We used immunohistochemistry to analyze MIB-1 labeling in a series of feline dysplastic and neoplastic mammary tissues to determine whether this antibody would give more information on the clinical behavior of invasive FMC in a 2-year follow-up study. We also considered the usefulness of tumor grading as a prognostic indicator.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
All the mammary gland specimens used in this study were retrieved from the archives of the Tumour Registry at the Department of Animal Pathology, University of Pisa between January 1997 and December 1998. The samples were surgically obtained by simple mastectomy or block dissection from 75 female cats of different breeds (52 European Domestic Shorthair cats, 8 Siamese, and 15 Persians) ages 2–19 years ( ± SD = 10.3 ± 2.6 years).

The queens included in the study were examined and surgically treated at the Veterinary Teaching Hospital (Clinic Department, School of Veterinary Medicine, University of Pisa) or by practitioners in the surrounding areas. After anamnesis collection, including age, breed, body size, history of ovariohysterectomy, and prevention of estrus with hormonal treatment, a complete physical examination was done. Information on tumor size (maximum length), adherence to underlying tissues, and skin ulceration were also recorded. All the cats included in the study were followed for at least 2 years after surgery by the referring veterinary surgeons to evaluate the postsurgery course of the disease. Overall survival was defined as the time from the day of diagnosis until the day of death or last follow-up.

Ten normal mammary tissues were also studied. These samples were from specific-pathogen-free cats (Iffa Credo, L'Asbrege, France) used as negative controls in a feline immunodeficiency virus (FIV) vaccination program and housed in a climate-controlled animal facility (Techniplast, Gazzada, Italy) of the Retrovirus Centre of the University of Pisa, under conditions stipulated by European Community law.

Representative portions of each mammary sample were fixed in 10% buffered formalin and routinely embedded in paraffin. Five-micrometer-thick sections were stained with hematoxylin and eosin (HE) for histologic evaluation; additional 5-µm sections were used for immunohistochemical studies. The lesions were classified according to the World Health Organization (WHO) classification,9 and tumors displaying different features were classified according to the most pronounced histologic differentiation. Presence of lymphatic or stromal invasion was also recorded.

Histologic grading was performed on HE-stained sections according to the classification proposed by Elston and Ellis5 and previously used to determine the grade of FMCs.2 Histologic grading mainly involved invasive carcinomas; noninvasive tumors were excluded from this part of the study. According to the Elston and Ellis method,5 the overall grade of an individual tumor was derived from the assessment of three morphologic features: degree of tubule formation, degree of nuclear and cellular pleomorphism, and mitotic count. To score the degree of tubular formation, two complete sections from different areas of each tumor were examined, and the proportion of tumor showing tubular formation was determined. When >75% of the examined area displayed definite tubular formation, a score of 1 point was given, from 10% to 75% was given 2 points, and less than 10% was given 3 points. Nuclear pleomorphism was scored qualitatively (1 point when nuclei were small and regular with uniform chromatin, 2 points when cells were larger than normal with vescicular nuclei and clearly visible nucleoli, and 3 points when cells differed in size and shape with prominent and multiple nucleoli). Mitotic count was evaluated quantitatively (1 point was given for >7 mitoses/10 fields; 2 points for 8–15 mitoses/10 fields, and 3 points for >15 mitoses/10 fields). After adding together the score of each category, the tumor grade was obtained as follows: well-differentiated carcinoma (grade I), 3–5 points; moderately differentiated carcinoma (grade II), 6 or 7 points; and poorly differentiated carcinoma (grade III), 8 or 9 points.

Five-micrometer-thick sections on poly-L-lysine–coated glass slides were deparaffinised in xylene and rehydrated in alcohol. Endogenous peroxidase activity was blocked by incubating the slides for 5 minutes at 37 C in Endo/Blocker (BiØmeda Corp., Foster City, CA) solution diluted in methanol. To unmask the antigen, the slides were microwaved in 10 mM citrate buffer, pH 6, for 5 minutes at 750 W (three times). After blocking nonspecific staining with normal goat serum, the sections were incubated with the primary mouse monoclonal antibody MIB-1 (DBA, Milano, Italy) diluted 1:50 in phosophate-buffered saline solution (PBS) for 12 hours at room temperature in a moist chamber. Sections were extensively washed in PBS and then incubated with a biotinylated affinity-purified goat anti-mouse secondary antibody (Biogenex Laboratories, San Ramon, CA) for 30 minutes. Section were again washed before incubation for 10 minutes in a streptavidin–biotinylated horseradish peroxidase complex (Biospa, Milan, Italy), and the reaction was developed using a aminoethylcarbazole substrate (AEC, BiØmeda Corp.) for 10 minutes. Finally, the sections were counterstained with hematoxylin, dehydrated, and mounted. Positive controls were included in each staining and consisted of the germinal center of a hyperplastic lymph node from an FIV-infected cat. Negative controls were obtained both by omitting the primary antibody and by using murine subclass-matched (IgG1) unrelatd primary monoclonal antibody. The evaluation of MIB-1 labeling index (MIB-1 I) was assessed at the periphery of the lesions, where the number of positive cells per 1,000 cells examined were counted. This procedure was performed with 10 representative tumor areas from each slide.

Statistical analysis was performed using the statistical package SPSS Advanced Statistics 7.5 (SPSS Inc., Chicago, IL). The analysis of variance (ANOVA) was determined, and the difference between groups was evaluated with Bonferroni's test. Curves for overall survival were estimated by the Kaplan–Meier method.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
The 75 samples examined consisted of 57 of FMC, 11 of feline mammary hyperplasia (FMH), and 7 of mammary adenosis. Of the 57 tumors examined, nine (15.8%) were in situ carcinomas, and 48 (84.2%) were invasive carcinomas. Based on the WHO classification, papillary carcinoma was the most common type of invasive carcinoma (22/48, 45.8%), followed by solid carcinomas (14/48, 29.2%), tubular carcinomas (8/48, 16.7%), and papillary cystic carcinomas (4/48, 8.3%).

Histological grading of the 48 invasive carcinomas revealed that 16 (33.3%) were well-differentiated carcinomas (WDCs; grade I, Fig. 1), 23 (47.9%) were moderately differentiated carcinomas (MDCs; grade II, Fig. 2), and nine (18.7%) were poorly differentiated carcinomas (PDCs; grade III, Fig. 3). The relationship between the results of histologic classification and tumor grading is detailed in Table 1. All the tubular and papillary cystic carcinomas were WDCs or MDCs, and solid carcinomas were mostly MDCs and PDCs.



View larger version (153K):
[in this window]
[in a new window]
  		Fig. 1. Mammary gland; cat No. 26. Well-differentiated carcinoma (grade I) with a high degree of tubule formation and relatively uniform cells and nuclei. HE. Bar = 50 µm.
Fig. 2. Mammary gland; cat No. 25. Moderately differentiated carcinoma (grade II). The tumor has a high degree of tubule formation and shows cells larger than normal with vescicular nuclei and high mitotic activity. HE. Bar = 50 µm.
Fig. 3. Mammary gland; cat No. 29. Poorly differentiated carcinoma (grade III) showing lack of tubule formation, large and vescicular nuclei with prominent nucleoli, and high mitotic index. HE. Bar = 50 µm.
Fig. 4. Mammary gland; cat No. 2. MIB-1 immunoreactivity is present in many nuclei (arrows). Streptavidin–biotin–peroxidase method, Harris' hematoxylin counterstain. Bar = 125 µm.

 

View this table:
[in this window]
[in a new window]
  		Table 1. Relationship between the tumor histologic type according to the WHO classification9 and grading of the invasive feline mammary carcinomas.5

 
In lymph node central sections, MIB-1 produced nuclear staining of germinal center cells, predominantly centroblasts. The staining pattern of MIB-1 antibody-positive cells in control and mammary gland tissue sections was nuclear (either diffuse or granular), and mitotic figures when present were always strongly labeled (Fig. 4).

Normal mammary glands showed rare MIB-1–positive cells. The MIB-1 I in dysplastic and neoplastic mammary tissues is presented in Fig. 5. The MIB-1 I was higher in FMH and invasive carcinomas; the latter had an MIB-1 I significantly higher than that of adenosis (P = 0.005) and noninvasive (in situ) carcinomas (P = 0.006). No significant difference in MIB-1 I was found between invasive carcinomas and FMHs.



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 5. Mib-1 labeling index in normal mammary tissues, mammary adenosis, feline mammary hyperplasia (FMH), and in situ and invasive feline mammary carcinomas (FMC). In the boxplot, the box encloses cases within the 25th to 75th percentiles, the broad horizontal line within each distribution is the median, the upper bar represents the largest observed value that is not an outlier, and the lower bar represents the smallest observed value that is not an outlier. {circ} and identification number = value >1.5 box lengths from the 75th percentile (outlier); * and identification number = value >3 box lengths from the 75th percentile (extreme).

 
Invasive carcinomas were segregated by MIB-1 I below and above the median value (18.7%), and the relationship with histologic type, grading of tumor, lymphatic invasion, and tumor size is shown in Table 2.


View this table:
[in this window]
[in a new window]
  		Table 2. Correlation between MIB-1 labeling index and histologic type, grading, lymphatic invasion, and size of 48 invasive feline mammary carcinomas.

 
High MIB-1 I showed a borderline significant association with lymphatic vessels invasion (P = 0.048) but no correlation with histologic type, grading, and size of tumor. Concerning histologic type, only 25% of tubular and papillary cystic carcionmas, 50% of papillary carcinomas, and 71.4% of the solid carcinomas had an MIB-1 I higher than 18.7% (Table 2). No differences were detected on the basis of grading or size of tumor.

All the queens with FMH and noninvasive (in situ) carcinoma were alive and well at the end of the 2-year trial, without any sign of local or metastatic recurrence. Twenty-one (43.7%) of the 48 queens with invasive carcinoma (group A) were alive and well at the end of the 2-year follow-up, and 27 (58.2%; group B) had died. At the end of the first year of study, 24 of the 27 queens of group B had already died. There was no significant difference in the age at tumor diagnosis between group A ( ± SD = 10.3 ± 2.3 years) and group B (10.7 ± 2.8 years) (P = 0.24).

Neoplastic cells of group B queens showed higher MIB-1 I (22.4 ± 10.7) than did those of group A cats (18.7 ± 7.7), but this difference was not significant (P = 0.157). The relationship between MIB-1 I by quartiles and the postsurgery deaths within 2 years is presented in Table 3. Even if a significant association between the survival time and the MIB-1 I was not evident, the queens with an MIB-1 I of >27.2% had a poor prognosis compared with queens of the other quartiles.


View this table:
[in this window]
[in a new window]
  		Table 3. Quartiles of MIB-1 labeling index and deaths in 48 cats with infiltrating mammary tumors during the 2 years after surgery.

 
The lack of correlation between higher MIB-1 I and an unfavourable prognosis was also demonstrated by the estimation of curves for overal survival. There was no significant association between overall survival and higher MIB-1 I (>18.7%) in the group of cats with invasive carcinomas (P = 0.0540; Fig. 6). No significant differences in the course of the disease were observed when the histotype of invasive carcinomas was considered (P = 0.1193).



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 6. Overall survival curves for the group of 48 queens with invasive carcinomas with low MIB-1 labeling index (<=18.7% {square}) and high MIB-1 labeling index (>18.7% {blacksquare}) (P = 0.0540).

 
The number of tumor-related deaths at the end of the follow-up period was 6/16 (37.5%) in queens with WDCs, 12/23 (52.2%) in queens with MDCs, and 9/9 (100%) in queens with PDCs. The high predictive value of tumor grading was confirmed by estimation of curves for overall survival; PDCs were associated with a shorter overall survival (P = 0.0040; Fig. 7).



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 7. Overall survival curves for the group of 48 queens with invasive carcinomas divided according to the tumor grade.5 Queens had poorly differentiated carcinomas ({blacktriangleup}), moderately differentiated carcinomas ({blacksquare}), or well-differentiated carcinomas ({square}) (P = 0.0040).

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In this study, we examined the relationship between the assessment of cellular proliferation and tumor grading and the clinical behavior of FMCs. All the cats with invasive carcinomas were kept under observation for 24 months after resection. As previously observed, most queens with progressive disease had an overall survival of <1 year.23 Only 3 of the 24 queens that died during the follow-up survived for >12 months after the detection of a tumor.

Our study confirmed the usefulness of MIB-1 antibody for the assessment of cell kinetics by immunohistochemical localization of the Ki-67 antigen on feline formalin-fixed, paraffin-embedded tissues routinely processed for histochemistry.

Normal mammary gland tissues showed a low proliferative rate (<1%). Mammary tissues with adenosis maintained a proliferative rate similar to that of normal tissues, and noninvasive (in situ) carcinomas had low MIB-1 I. In contrast, MIB-1 I was higher in invasive FMCs and in FMHs.

In spite of these results, a lack of significant prognostic importance of MIB-1 I in mammary carcinomas was found, even though higher mortality was observed in queens with tumors displaying elevated MIB-1 I. As with canine mammary tumors, the prognostic relevance of kinetic parameters for FMCs remains to be determined. Previous studies demonstrated that mitotic index and argyrophilic nucleolar organizer region counts were significantly correlated with the course of mammary carcinomas in cats,3,23 but few studies have investigated MIB-1 as a prognostic factor for these tumors. A previous investigation, carried out on FMCs, demonstrated that the Ki-67 index was a useful tool for identifying tumors with a more aggressive course.4 Similar resutls were obtained in a study on canine mammary tumors: multivariate analysis concerning metastasis, disease-free survival, and overall survival revealed that the Ki-67 index had a prognostic value.19 Notably, however, another study dealing with Ki-67 immunohistochemistry in canine mammary tumors reported a lack of prognostic information of this marker.15 Even though the diagnostic and prognostic value of Ki-67 immunostaining of human tumors has been widely documented and accepted,6,12 some researchers have not found an association between Ki-67 and disease-free survival.14,21 This discrepancy in results has been explained based on the criteria employed in dividing the patients into groups.12 In canine mammary tumors, the contrasting results concerning the prognostic information on the proliferative activity detected by Ki-67 immunohistochemistry were related to the heterogeneity in the prevalence and biologic behavior of the various histologic types.4 In the present study, we used a population similar to that employed in the previous study on feline mammary tumors so that the results of the two studies could be compared.

In the present study, other factors such as cat age, tumor histologic type, and tumor grade were not significantly related to MIB-1 I, but MIB-1 expression had a borderline correlation with presence of lymphatic invasion. This finding is in agreement with those of other studies where no correlations were found between proliferation indexes and morphologic appearance of mammary carcinomas in cats4 and dogs.20

Animal age and tumor histologic type were also not correlated with survival, but tumor grading, determined using the Elston and Ellis method,5 had high predictive value, as shown by survival curves. Comparable results have been found in a previous study,2 especially with respect to grade I and grade III carcinomas.

MIB-1 I measured in paraffin-embedded sections is a useful method for assessing proliferation in a routine setting. However, the results of this and other studies on MIB-1 expression as a prognostic factor for survival in FMC have produced conflicting results, and at this time the data do not support the use of MIB-1 I in clinical decision making. To reach a definitive conclusion on the value of this index, it will be necessary to develop a standardized methodology to compare the results obtained in different studies. More information is needed to determine whether the use of this marker in association with histologic grading will add new prognostic information for the treatment of FMCs.


   Acknowledgments
 
This work was supported by grants from Ministero dell'Universitá e della Ricerca Scientifica, Rome, Italy.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Carpenter JL, Andrews LK, Holtzworth J: Tumours and tumour-like lesions. In: Diseases of the Cat: Medicine and Surgery, ed. Holtzworth J, vol. 1, pp 406-596, WB Saunders, London, England 1987
  2. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M: Tumour grading and the one-year post-surgical prognosis in feline mammary carcimomas. J Comp Pathol 119:263-275, 1998[Medline]
  3. Castagnaro M, Casalone C, Ru G, Nervi GC, Bozzetta E, Caramelli M: Argyrophilic nucleolar organizer regions (AgNORs) count as indicator of post-surgical prognosis in feline mammary carcinomas. Res Vet Sci 64:97-100, 1998[Medline]
  4. Castagnaro M, De Maria R, Bozzetta E, Ru G, Casalne C, Biolatti B, Caramelli M: Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas. Res Vet Sci 65:223-226, 1998[CrossRef][Medline]
  5. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. Value of histological grade breast cancer: experience from a large study with long term follow-up. Histopathology 19:403-410, 1991[Medline]
  6. Gasparini G, Boracchi P, Verderio P, Bevilacqua P: Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57:822-829, 1994[Medline]
  7. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984[Abstract]
  8. Gerdes J, Li L, Schleuter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD: Immunobiochemical and molecular biologic characterisation of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873, 1991[Abstract]
  9. Hampe JF, Misdorp W: Tumours and dysplasias of the mammary gland. Bull World Health Organ 50:111-133, 1974[Medline]
  10. Hayden DW, Nielsen SW: Feline mammary tumours. J Small Anim Pract 12:697-698, 1971
  11. Hayes AA, Mooney S: Feline mammary tumours. Vet Clin North Am Small Anim Pract 15:513-520, 1985[Medline]
  12. Jansen RLH, Hupperets PSGJ, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC, Hillen HFP: MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460-465, 1998[Medline]
  13. Joling R, Broekhuizen R, de Weger RA, Rottier PJ, Egberink H: Immunohistochemical demonstration of cellular antigens of the cat defined by anti-human antibodies. Vet Immunol Immunopathol 53:115-127, 1996[CrossRef][Medline]
  14. Keshgegian AA, Cnaan A: Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104:42-49, 1995[Medline]
  15. Löhr CV, Tiefke JP, Failing K, Weiss E: Characterization of the proliferative state in canine mammary tumours by the standardized AgNOR method with postfixation and immunohistologic detection of Ki-67 and PCNA. Vet Pathol 34:212-221, 1997[Abstract]
  16. MacEwen EG, Hayes AA, Harvey J, Patnaik AK, Mooney S, Passe S: Prognostic factors for feline mammary tumours. J Am Vet Med Assoc 185:201-204, 1984[Medline]
  17. MacEwen EG, Withrow SJ: Tumours of the mammary gland. In: Small Animal Clinical Oncology, ed. MacEwen EG, Withrow SJ, 2nd ed., pp 356-379, WB Saunders, London, England 1996
  18. Moulton JE: Tumours of the mammary gland. In: Tumours in Domestic Animals, ed. Moulton JE, 4th ed., pp 518-552, University of California Press, Los Angeles, CA 1990
  19. Pena LL, Nieto AI, Perez-Alenza D, Cuesta P, Castano M: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathological variables. J Vet Diagn Invest 10:237-246, 1998[Abstract/Free Full Text]
  20. Preziosi R, Sarli G, Benazzi C, Marcato PS: Detection of proliferatine cell nuclear antigen (PCNA) in canine and feline mammary tumours. J Comp Pathol 113:301-313, 1995[CrossRef][Medline]
  21. Rudas M, Gnant MFX, Mittbock M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labelling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 32:165-175, 1994[CrossRef][Medline]
  22. Scholtzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311-322, 2000[CrossRef][Medline]
  23. Weijer K, Hart AAM: Prognostic factors in feline mammary carcinomas. J Natl Cancer Inst 70:709-716, 1983
Request reprints from Dr. A. Poli, Department of Animal Pathology, School of Veterinary Medicine, Viale delle Piagge, 2 I-56124 Pisa (Italy). E-mail: apoli{at}vet.unipi.it.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Vet PatholHome page
F. Seixas, C. Palmeira, M. A. Pires, and C. Lopes
Mammary Invasive Micropapillary Carcinoma in Cats: Clinicopathologic Features and Nuclear DNA Content
Vet. Pathol., November 1, 2007; 44(6): 842 - 848.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
D. McAloose, L. Munson, and D. K. Naydan
Histologic Features of Mammary Carcinomas in Zoo Felids Treated with Melengestrol Acetate (MGA) Contraceptives
Vet. Pathol., May 1, 2007; 44(3): 320 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. M. Gutschalk, C. C. Herold-Mende, N. E. Fusenig, and M. M. Mueller
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Promote Malignant Growth of Cells from Head and Neck Squamous Cell Carcinomas In vivo
Cancer Res., August 15, 2006; 66(16): 8026 - 8036.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
F. Millanta, G. Lazzeri, I. Vannozzi, P. Viacava, and A. Poli
Correlation of Vascular Endothelial Growth Factor Expression to Overall Survival in Feline Invasive Mammary Carcinomas
Vet. Pathol., November 1, 2002; 39(6): 690 - 696.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millanta, F.
Right arrow Articles by Poli, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millanta, F.
Right arrow Articles by Poli, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS